[go: up one dir, main page]

HRP20211398T1 - Oralne formulacije citidinskih analoga i postupci njihove uporabe - Google Patents

Oralne formulacije citidinskih analoga i postupci njihove uporabe Download PDF

Info

Publication number
HRP20211398T1
HRP20211398T1 HRP20211398TT HRP20211398T HRP20211398T1 HR P20211398 T1 HRP20211398 T1 HR P20211398T1 HR P20211398T T HRP20211398T T HR P20211398TT HR P20211398 T HRP20211398 T HR P20211398T HR P20211398 T1 HRP20211398 T1 HR P20211398T1
Authority
HR
Croatia
Prior art keywords
methods
oral formulations
cytidine analogs
preparation
azacytidine
Prior art date
Application number
HRP20211398TT
Other languages
English (en)
Inventor
Jeffrey B. Etter
Mei Lai
Jay T. Backstrom
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211398(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HRP20211398T1 publication Critical patent/HRP20211398T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (1)

1. Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu 5-azacitidina za uporabu u postupku liječenja pojedinca koji ima akutnu mijeloičnu leukemiju, pri čemu navedeni postupak obuhvaća oralnu primjenu spomenutog farmaceutskog pripravka i pritom se kod pripravka radi o pripravku s trenutnim oslobađanjem i koji oslobađa 5-azacitidin uglavnom u želucu nakon oralne primjene kod pojedinca.
HRP20211398TT 2008-05-15 2021-09-02 Oralne formulacije citidinskih analoga i postupci njihove uporabe HRP20211398T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
EP19213148.0A EP3692983B1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20211398T1 true HRP20211398T1 (hr) 2021-12-10

Family

ID=40941609

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20231439TT HRP20231439T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije citidinskih analoga i postupci za njihovu uporabu
HRP20190100TT HRP20190100T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije analoga citidina i postupci za njihovu upotrebu
HRP20221064TT HRP20221064T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije citidinskih analoga i postupci njihove uporabe
HRP20200096TT HRP20200096T1 (hr) 2008-05-15 2020-01-21 Oralne formulacije analoga citidina i postupci za njihovu upotrebu
HRP20211398TT HRP20211398T1 (hr) 2008-05-15 2021-09-02 Oralne formulacije citidinskih analoga i postupci njihove uporabe

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HRP20231439TT HRP20231439T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije citidinskih analoga i postupci za njihovu uporabu
HRP20190100TT HRP20190100T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije analoga citidina i postupci za njihovu upotrebu
HRP20221064TT HRP20221064T1 (hr) 2008-05-15 2009-05-14 Oralne formulacije citidinskih analoga i postupci njihove uporabe
HRP20200096TT HRP20200096T1 (hr) 2008-05-15 2020-01-21 Oralne formulacije analoga citidina i postupci za njihovu upotrebu

Country Status (34)

Country Link
US (12) US8846628B2 (hr)
EP (6) EP2299984B1 (hr)
JP (3) JP2011520880A (hr)
KR (1) KR101633134B1 (hr)
CN (3) CN102099018B (hr)
AR (1) AR071808A1 (hr)
AU (3) AU2009246926B2 (hr)
BR (1) BRPI0912717A2 (hr)
CA (3) CA3094590A1 (hr)
CL (2) CL2009001170A1 (hr)
CO (1) CO6300930A2 (hr)
CR (1) CR11789A (hr)
CY (3) CY1121350T1 (hr)
DK (5) DK3782611T3 (hr)
EC (1) ECSP10010665A (hr)
ES (5) ES2893785T3 (hr)
FI (1) FI3782612T3 (hr)
HR (5) HRP20231439T1 (hr)
HU (5) HUE055911T2 (hr)
IL (2) IL209307A (hr)
LT (5) LT2695609T (hr)
MX (2) MX363023B (hr)
MY (1) MY161593A (hr)
NI (1) NI201000193A (hr)
NZ (3) NZ602833A (hr)
PE (2) PE20091971A1 (hr)
PL (5) PL3782611T3 (hr)
PT (5) PT2695609T (hr)
RU (3) RU2476207C2 (hr)
SG (1) SG193206A1 (hr)
SI (5) SI2695609T1 (hr)
TW (3) TWI522103B (hr)
WO (1) WO2009139888A1 (hr)
ZA (1) ZA201008229B (hr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
EP2211870A1 (en) * 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) * 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2575774A4 (en) * 2010-06-07 2014-01-22 Abraxis Bioscience Llc COMBINATION THERAPY PROCEDURE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
BR112013025167A2 (pt) 2011-03-31 2019-09-24 Celgene Int Sarl processo para preparar 5-azacitidina, ou um sal, solvato, hidrato, ou seu polimorfo, sal de 5-azacitidina, 5-azacitidina, ou um sal, solvato, hidrato, ou polimorfo
CN104168884A (zh) * 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
JP6444883B2 (ja) * 2012-11-29 2018-12-26 タカラ バイオ ヨーロッパ アーベー 哺乳類多能性幹細胞由来の内胚葉細胞を産生するための改良された方法
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
US20150359810A1 (en) * 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
ES2940302T3 (es) 2014-08-22 2023-05-05 Celgene Corp Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
CN107847448A (zh) * 2015-05-22 2018-03-27 诺华股份有限公司 药物组合物
MA43000B1 (fr) * 2015-10-15 2021-11-30 Celgene Corp Polythérapie pour le traitement de tumeurs malignes
BR112018007671B1 (pt) 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
ES2862730T3 (es) * 2015-10-15 2021-10-07 Celgene Corp Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda
WO2017096357A1 (en) 2015-12-03 2017-06-08 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
EP3986404A1 (en) * 2019-06-20 2022-04-27 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP7680762B2 (ja) * 2019-09-25 2025-05-21 アードバーク・セラピューティクス・インコーポレイテッド 経口速放出性医薬組成物および減量治療の方法
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
WO2021125261A1 (ja) * 2019-12-18 2021-06-24 一般社団法人 東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021136381A1 (zh) * 2019-12-31 2021-07-08 江苏亚虹医药科技股份有限公司 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CA3176543A1 (en) 2020-04-23 2021-10-28 Mark J. Suto Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
KR20230061354A (ko) 2020-07-23 2023-05-08 써던 리서취 인스티튜트 5-아자-4'-티오-2'-데옥시사이티딘의 다형체
WO2022133323A1 (en) * 2020-12-18 2022-06-23 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (hr) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
ATE126510T1 (de) 1989-05-10 1995-09-15 Hoffmann La Roche Herstellung von isochinolinderivaten.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
ES2195970T3 (es) 1996-10-16 2003-12-16 Ribapharm Inc L-ribavirina y usos de la misma.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
US6890547B1 (en) 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1399159A4 (en) 2001-06-01 2007-02-14 Cytovia Inc 4-SUBSTITUTED 1- (ARYLMETHYLIDEN) THIOSEMICARBAZIDE, 4-SUBSTITUTED 1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS AND THEIR USE
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003286836A1 (en) 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US7144876B2 (en) 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CA2526908A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
CN101856348A (zh) * 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
US20110288042A1 (en) 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2205073A4 (en) 2007-09-26 2013-03-06 Sinai School Medicine AZACYTIDINE ANALOGS AND USES THEREOF
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
ES2400779T3 (es) 2008-08-06 2013-04-12 Sicor, Inc. Proceso para preparar un producto intermedio de azacitidina
KR101660549B1 (ko) 2008-08-08 2016-09-27 시노팜 타이완 리미티드 ５―아자시토신 뉴클레오시드 및 이의 유도체의 제조 방법
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
BR112013025167A2 (pt) 2011-03-31 2019-09-24 Celgene Int Sarl processo para preparar 5-azacitidina, ou um sal, solvato, hidrato, ou seu polimorfo, sal de 5-azacitidina, 5-azacitidina, ou um sal, solvato, hidrato, ou polimorfo
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CN104168884A (zh) 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法

Also Published As

Publication number Publication date
RU2765076C2 (ru) 2022-01-25
MX2010012470A (es) 2010-12-02
CY1124720T1 (el) 2022-07-22
CA2761582C (en) 2022-06-07
JP2015110575A (ja) 2015-06-18
EP3782611B1 (en) 2022-07-06
HUE064677T2 (hu) 2024-04-28
CA3094590A1 (en) 2009-11-19
HUE047707T2 (hu) 2020-05-28
US20220079964A1 (en) 2022-03-17
CY1121350T1 (el) 2020-05-29
HRP20200096T1 (hr) 2020-04-03
DK3782611T3 (da) 2022-09-05
US20230255996A1 (en) 2023-08-17
US20200316099A1 (en) 2020-10-08
CN103479586A (zh) 2014-01-01
TWI522103B (zh) 2016-02-21
KR20110015629A (ko) 2011-02-16
PL2299984T3 (pl) 2019-07-31
US20220105118A1 (en) 2022-04-07
RU2012147739A (ru) 2014-05-20
HRP20221064T1 (hr) 2022-11-11
CN105535008A (zh) 2016-05-04
SI2695609T1 (sl) 2020-03-31
ES2969144T3 (es) 2024-05-16
CA3094580C (en) 2021-05-18
PT3692983T (pt) 2021-11-08
PE20091971A1 (es) 2010-01-15
SI3782612T1 (sl) 2024-02-29
IL238087B (en) 2019-01-31
AU2009246926B2 (en) 2014-06-26
AU2013202665A1 (en) 2013-05-02
CL2009001170A1 (es) 2010-06-04
IL209307A0 (en) 2011-01-31
TW201513869A (zh) 2015-04-16
PL3692983T3 (pl) 2021-12-27
MY161593A (en) 2017-04-28
CY1122681T1 (el) 2020-10-14
RU2010151428A (ru) 2012-06-20
US10646503B2 (en) 2020-05-12
CN102099018A (zh) 2011-06-15
PL3782611T3 (pl) 2022-11-07
US12053482B2 (en) 2024-08-06
CN103479586B (zh) 2017-03-01
HUE055911T2 (hu) 2021-12-28
US20200101095A1 (en) 2020-04-02
US20180153916A1 (en) 2018-06-07
EP3692983A1 (en) 2020-08-12
AU2015202884B2 (en) 2017-02-23
US20250082661A1 (en) 2025-03-13
FI3782612T3 (fi) 2024-01-16
JP2017137326A (ja) 2017-08-10
US20190231803A1 (en) 2019-08-01
EP3782611A1 (en) 2021-02-24
CN102099018B (zh) 2016-01-13
IL209307A (en) 2016-02-29
DK2695609T3 (da) 2020-02-10
PE20142440A1 (es) 2015-01-28
HUE042825T2 (hu) 2019-07-29
EP4327888A3 (en) 2024-05-22
TWI618538B (zh) 2018-03-21
EP2299984A1 (en) 2011-03-30
US10463683B2 (en) 2019-11-05
RU2018109222A3 (hr) 2021-07-02
NI201000193A (es) 2011-08-01
EP4327888A2 (en) 2024-02-28
JP6426778B2 (ja) 2018-11-21
ES2927556T3 (es) 2022-11-08
LT2299984T (lt) 2019-03-25
US20230241086A1 (en) 2023-08-03
EP3782612B1 (en) 2023-11-08
PT2695609T (pt) 2020-03-02
RU2476207C2 (ru) 2013-02-27
AU2015202884A1 (en) 2015-06-18
EP3692983B1 (en) 2021-08-11
JP2011520880A (ja) 2011-07-21
LT3782612T (lt) 2023-12-27
ZA201008229B (en) 2012-02-29
CA2761582A1 (en) 2009-11-19
US10220050B2 (en) 2019-03-05
LT3782611T (lt) 2022-10-10
TW201006478A (en) 2010-02-16
HUE059635T2 (hu) 2022-12-28
AU2009246926A1 (en) 2009-11-19
RU2018109222A (ru) 2019-09-17
NZ602833A (en) 2014-04-30
DK3692983T3 (da) 2021-09-20
BRPI0912717A2 (pt) 2014-12-23
PT3782611T (pt) 2022-11-18
DK3782612T3 (da) 2024-01-15
CA3094580A1 (en) 2009-11-19
DK2299984T3 (en) 2019-03-04
EP2695609A1 (en) 2014-02-12
LT3692983T (lt) 2021-11-10
TW201729817A (zh) 2017-09-01
NZ589437A (en) 2012-11-30
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
SI3692983T1 (sl) 2021-11-30
ECSP10010665A (es) 2011-01-31
CO6300930A2 (es) 2011-07-21
US20090286752A1 (en) 2009-11-19
US8846628B2 (en) 2014-09-30
SI3782611T1 (sl) 2022-10-28
US11571436B2 (en) 2023-02-07
EP2695609B1 (en) 2019-12-11
MX363023B (es) 2019-03-05
ES2712506T3 (es) 2019-05-13
HRP20231439T1 (hr) 2024-03-01
KR101633134B1 (ko) 2016-06-23
JP6105547B2 (ja) 2017-03-29
CR11789A (es) 2011-02-21
PT2299984T (pt) 2019-02-25
NZ623495A (en) 2015-08-28
EP3782612A1 (en) 2021-02-24
PT3782612T (pt) 2024-01-18
CL2013001097A1 (es) 2013-11-29
AU2013202665B2 (en) 2015-06-25
US20150374732A1 (en) 2015-12-31
AR071808A1 (es) 2010-07-14
HRP20190100T1 (hr) 2019-04-05
PL2695609T3 (pl) 2020-05-18
US20150056280A1 (en) 2015-02-26
SI2299984T1 (sl) 2019-04-30
EP2299984B1 (en) 2018-11-28
LT2695609T (lt) 2020-02-10
ES2893785T3 (es) 2022-02-10
ES2774226T3 (es) 2020-07-17
WO2009139888A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
HRP20211398T1 (hr) Oralne formulacije citidinskih analoga i postupci njihove uporabe
HRP20210670T1 (hr) Pripravci za liječenje raka
HRP20161444T1 (hr) Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
HRP20220025T1 (hr) Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja
WO2011079239A3 (en) Combination tablet with chewable outer layer
JP2007527914A5 (hr)
JP2015523407A5 (hr)
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
JP2015038135A5 (hr)
MX2020012310A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
HRP20210537T1 (hr) Upotreba inhibitora faktora induciranog hipoksijom
HRP20191723T1 (hr) Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa
HRP20200142T4 (hr) Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
CL2008000227A1 (es) Composicion farmaceutica que comprende una combinacion de uso oral de tramadol y ketoprofeno; y uso en el tratamiento del dolor.
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta
EP4110301A4 (en) Pharmaceutical composition for oral administration
JP2010526884A5 (hr)
JP2012097034A5 (hr)